La Paz University Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Doctor of Medicine and Psychiatrist at the Carlos III Day Hospital - La Paz University Hospital (Madrid)
Head of the Paediatric Haematology-Oncology Department at the Hospital Universitario La Paz.
Head of Section of the Hospital Paediatrics, Infectious and Tropical Diseases Department of the Hospital Universitario Infantil La Paz (Madrid)
Clinical laboratory geneticist in the Molecular Ophthalmogenetics section of the Institute of Medical Genetics (INGEMM) and Molecular Genetics of the Hospital Universitario La Paz
Head of the Cancer Epigenetics Laboratory at INGEMM and coordinator of Experimental Therapies and Biomarkers in Cancer at IdiPAZ, La Paz University Hospital
Cardiologist at the Hospital Universitario La Paz, representative of the Spanish Society of Cardiology in the National Committee for the Prevention of Smoking and member of the Tobacco Expert Group of the World Heart Federation
A team of researchers from the United Kingdom has conducted a phase 2/3 clinical trial in people with a psychotic disorder to study the efficacy of interaction with a digital avatar in alleviating the discomfort generated by hearing voices. After analyzing it in 345 people, they conclude that it can reduce the frequency of occurrence at 16 and 28 weeks. The discomfort provoked is reduced at 16 weeks, but not at 28 weeks. The team publishes the results in the journal Nature Medicine.
A phase 2 clinical trial has tested the efficacy and safety of a transcranial magnetic stimulation device used at home to treat major depression in 174 patients. After dividing them into two groups, one group received the treatment and the other a placebo procedure. After ten weeks, both groups had improved their symptoms, but the improvement in the active treatment group was 0.4 points greater on the Hamilton depression scale. According to the authors, who publish the results in the journal Nature Medicine, ‘it could potentially serve as a first-line treatment for major depression’.
An international team of researchers has conducted a study in which they conclude that increased activity of the brain amygdala detected by magnetic resonance imaging is associated with an increased risk of developing symptoms of depression in pregnant women. According to the authors, the finding could be used to identify those who are more likely to suffer from postpartum depression. The results of the study, still in prepublication form and not yet peer-reviewed, will be presented at the ECNP (European College of Neuropsychopharmacology) conference.
The mental health of young people has deteriorated over the last two decades and is entering a dangerous phase, according to a new Commission by The Lancet Psychiatry. Several global factors are involved, including inaction on climate change, intergenerational inequality, and adversity linked to the COVID-19 pandemic.
A team of researchers has analysed data from more than 650,000 residents in Sweden and concluded that the genetic predisposition of peers - especially in high school - influences one's risk of developing anxiety, depression or drug abuse in the future. According to the authors, who publish the results in the American Journal of Psychiatry, this relationship appears "even after controlling statistically for whether peers were affected or not".
The use of the antidepressants escitalopram, paroxetine, and duloxetine is associated with greater weight gain than the use of sertraline, according to the results of an analysis comparing data from more than 183,000 adults treated with one of eight types of antidepressants. Among these, bupropion is associated with the least weight gain, concludes the study, which is published in Annals of Internal Medicine.
The Lancet Psychiatry publishes the first meta-analysis of the incidence of antidepressant treatment discontinuation symptoms that includes data from more than 20,000 patients collected from 79 randomised controlled trials and observational studies. The study sought to distinguish between symptoms directly caused by medication discontinuation and other ‘non-specific’ symptoms that may be associated with patient or professional expectations (the nocebo effect). The study concludes that one in six to seven patients will experience one or more symptoms directly caused by stopping medication, and one in 35 are likely to experience severe symptoms.
The PsychENCODE consortium, established in 2015 and dedicated to illuminating the molecular mechanisms underlying schizophrenia, bipolar disorder, and autism spectrum disorder, presents findings based on the examination of human brains at the cellular level. The studies are published today in the journals Science, Science Translational Medicine and Science Advances.
A Finnish study involving more than 700,000 adolescents has found some risk of transmission of some mental disorders among classmates. The results are published in the journal JAMA Psychiatry.
The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.